PTC THERAPEUTICS INC (PTCT)       51.5  +0.82 (+1.62%)

51.5  +0.82 (+1.62%)

US69366J2006 - Common Stock - After market: 51.5 0 (0%)

PTC THERAPEUTICS INC51.5

NASDAQ:PTCT (10/4/2022, 7:00:01 PM)+0.82 (+1.62%)

After market: 51.5 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 08-04 2022-08-04/amc Earnings (Next) 10-27 2022-10-27/amc
Ins Owners 0.8% Inst Owners 103.4%
Market Cap 3.68B Shares 71.54M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 74.12
IPO 06-20 2013-06-20

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

PTCT Daily chart

Company Profile

PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically differentiated medicines. The company is headquartered in South Plainfield, New Jersey and currently employs 1,252 full-time employees. The company went IPO on 2013-06-20. The Company’s portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases. The firm has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). The Company’s gene therapy platform focuses on the development of therapies for rare and debilitating diseases of the nervous system (CNS). The Company’s splicing platform focuses on the development of therapies for diseases, such as SMA, that involve regulation of messenger RNA (mRNA) splicing in the cell.

Company Info

PTC THERAPEUTICS INC

100 Corporate Ct

South Plainfield NEW JERSEY 07080

P: 19082227000.0

CEO: Stuart W. Peltz

Employees: 1252

Website: https://www.ptcbio.com/

PTCT News

News Image16 days ago - PTC TherapeuticsAssociação de pacientes brasileira recebe STRIVE(TM) Award 2022 da PTC Therapeutics para distrofia muscular de Duchenne

/PRNewswire/ -- A PTC Therapeutics, Inc. (NASDAQ: PTCT) anuncia que uma associação de pacientes brasileira é uma das quatro ganhadoras do programa global...

News Imagea month ago - Newman Ferrara LLPNewman Ferrara LLP Announces Corporate Governance Investigations of PTC Therapeutics (PTCT)News Imagea month ago - Market News VideoPTC Therapeutics Larger Than S&P 500 Component PVHNews Imagea month ago - PTC Therapeutics, Inc.PTC Therapeutics to Participate at Upcoming Investor Conferences

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: Wells...

News Image2 months ago - PTC Therapeutics, Inc.PTC Therapeutics Provides a Corporate Update and Reports Second Quarter Financial Results

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the second quarter ending June 30, 2022. "We...

News Image3 months ago - PTC Therapeutics, Inc.PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2022 Financial Results

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its second quarter 2022...

PTCT Twits

Here you can normally see the latest stock twits on PTCT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example